I am for it also. It is a god idea!!
Garib
On 9 Nov 2007, at 13:56, Ian Tickle wrote:
I like it!
-- Ian
-----Original Message-----
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] On Behalf Of Eleanor Dodson
Sent: 09 November 2007 13:51
To: Phil Evans
Cc: [email protected]
Subject: Re: [ccp4bb] pointless (1.2.0) and enantiomorphic SG's
As I often say!!! The mtz format should carry point group and
alternate
SGs - then be upgraded when youknow the correct SG..
Eleanor
Phil Evans wrote:
It just picks the first in the list, to store in the output
MTZ file,
which can only handle one (92 < 96)
Phil
On 8 Nov 2007, at 22:26, Bryan W. Lepore wrote:
when pointless (1.2.0) finds enantiomorphic SG's, what is the
criterion for 'Selecting' one over the other?
e.g. i ran pointless on some tetragonal data, and the
enantiomorphs
SG92/SG96 are selected as strong candidates
Spacegroup TotProb SysAbsProb Reindex
Conditions
<P 41 21 2> ( 92) 0.956 0.956 00l:
l=4n, h00: h=2n (zones 1,2)
<P 43 21 2> ( 96) 0.956 0.956 00l:
l=4n, h00: h=2n (zones 1,2)
... then pointless reports :
Selecting space group P 41 21 2 as solutions are enantiomorphic
Best Solution space group P 41 21 2
... is that b/c pointless can only report one, and SG92
came up first?
-bryan
Disclaimer
This communication is confidential and may contain privileged
information intended solely for the named addressee(s). It may not
be used or disclosed except for the purpose for which it has been
sent. If you are not the intended recipient you must not review,
use, disclose, copy, distribute or take any action in reliance upon
it. If you have received this communication in error, please notify
Astex Therapeutics Ltd by emailing [EMAIL PROTECTED]
and destroy all copies of the message and any attached documents.
Astex Therapeutics Ltd monitors, controls and protects all its
messaging traffic in compliance with its corporate email policy.
The Company accepts no liability or responsibility for any onward
transmission or use of emails and attachments having left the Astex
Therapeutics domain. Unless expressly stated, opinions in this
message are those of the individual sender and not of Astex
Therapeutics Ltd. The recipient should check this email and any
attachments for the presence of computer viruses. Astex
Therapeutics Ltd accepts no liability for damage caused by any
virus transmitted by this email. E-mail is susceptible to data
corruption, interception, unauthorized amendment, and tampering,
Astex Therapeutics Ltd only send and receive e-mails on the basis
that the Company is not liable for any such alteration or any
consequences thereof.
Astex Therapeutics Ltd., Registered in England at 436 Cambridge
Science Park, Cambridge CB4 0QA under number 3751674
